Alnylam Pharmaceuticals (alny 1 09/15/27)
13F holders, Q3 2024 (September 30)8holders −2
3new positions
5sold out
$4.53avg. 13F price*
At the end of Q3 2024, 8 institutions reported holding Alnylam Pharmaceuticals (alny 1 09/15/27) in their 13F filings, down 2 from Q2 2024. 3 opened new positions and 5 sold out. The largest holders were Nomura Holdings Inc. ($19.8M), BNP PARIBAS ASSET MANAGEMENT Holding S.A. ($5.8M) and Bank of New York Mellon Corp ($702K).
- Company
- Alnylam Pharmaceuticals (alny 1 09/15/27)
- CUSIP
- 02043QAB3
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q2 2024 → Q3 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 3 | $162K |
| Exits | 5 | $52.6M |
All 13F filers, Q2 2024 → Q3 2024: 142,817 shares bought and 7,679,123 shares sold, net −7,536,306 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 8 holders
| Nomura Holdings Inc. | 0.15% | Add +6.4% | 71,923 | $19.8M |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | 0.01% | No change | 4,950,000 | $5.8M |
| Bank of New York Mellon Corp | 0.00% | No change | 600,000 | $702K |
| Sei Investments Co. | 0.00% | No change | 99,000 | $116K |
| Oppenheimer Asset Management Inc. | 0.00% | New | 85,000 | $99K |
| Stephens Inc. | 0.00% | New | 43,000 | $50K |
| Boussard & Gavaudan Investment Management LLP | 0.00% | New | 10,500 | $12K |
| EverSource Wealth Advisors, LLC | 0.00% | No change | 3,000 | $4K |
"% of holder's portfolio" is ALNYLAM PHARMACEUTICALS (ALNY 1 09/15/27)'s weight in each manager's 13F, not the share of Alnylam Pharmaceuticals (alny 1 09/15/27) the manager owns.